不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
探索弥漫性大 B 细胞淋巴瘤不断演变的治疗格局
英文原题：Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma.
查看英文原题
Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
弥漫性大B细胞淋巴瘤是非霍奇金淋巴瘤最常见的亚型，由一组在形态学、遗传学和临床上具有显著异质性的疾病组成。近期的若干进展影响了原本在过去几十年中基本停滞的治疗格局。我们将回顾一线治疗（POLARIX）、早期复发（ZUMA-7和TRANSFORM）以及多线复发（ZUMA-1、JULIET、TRANSCEND、L-MIND和LOTIS-2）阶段中改变实践的研究，并讨论随着双特异性抗体的出现，治疗格局可能如何演变。
展开英文摘要原文
Diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, comprises a heterogenous group of morphologically, genetically, and clinically distinct diseases. Several recent advances have affected the treatment landscape, which had been mostly stagnant for the past few decades.
We will review the practice-changing studies in frontline (POLARIX), early relapse (ZUMA-7 and TRANSFORM), and multiple recurrent (ZUMA-1, JULIET, TRANSCEND, L-MIND, and LOTIS-2) stages and discuss how the treatment landscape may evolve with the emergence of bispecific antibodies.
论文信息
- 作者
- Nastoupil LJ、Bartlett NL
- 第一作者单位
- University of Texas MD Anderson Cancer Center, Houston, TX.United States
- 通讯作者单位
- Washington University, Siteman Cancer Center, St Louis, MO.United States
- 文献类型
- 综述
- 期刊
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology2023 Feb 1
- 原文标识
- PubMed 36508700 · DOI 10.1200/JCO.22.01848